This is a working overview of mass spectrometry, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2026-08-01. Anything still debated is marked as such rather than presented as settled.
AOD-9604 drew attention in the 1990s and 2000s as a potential anti-obesity agent. Early work explored both injectable and oral routes, which is unusual for a peptide of this size. Animal studies reported changes in fat metabolism without the growth-promoting or insulin-like effects associated with full-length growth hormone. Subsequent human trials produced mixed or modest results, and the compound did not obtain regulatory approval for weight management in major markets. It remains known mainly through research literature, sports anti-doping listings, and non-approved supplement advertising.
AOD-9604 is prohibited in sport by the World Anti-Doping Agency under the peptide hormone class. Its presence in a sample can be detected through mass spectrometry-based methods, although the exact assay depends on the laboratory. In research settings, material is often supplied as a lyophilized powder for reconstitution. Buyers and researchers should note that products labeled AOD-9604 may vary in purity and actual peptide content. Analytical certificates and independent testing are common ways to verify identity, but no global harmonized standard exists for all commercial lots.
In laboratory settings, AOD-9604 is commonly supplied as a lyophilized powder and stored cold to limit degradation. Reconstituted solutions are typically kept refrigerated or frozen, depending on the buffer and concentration, and protected from repeated freeze-thaw cycles. Stability can be influenced by pH, temperature, and the presence of proteases. Purity is usually assessed by high-performance liquid chromatography and mass spectrometry. These practices support reproducibility, but they do not imply safety or efficacy for any human use.
Regulatory status: AOD-9604 is not approved as a therapeutic drug in the United States, European Union, or other major markets. It is listed by the World Anti-Doping Agency as a prohibited substance in sport, specifically under growth hormone fragments. Many jurisdictions restrict its sale for human consumption. Products marketed online may not meet pharmaceutical quality standards. The legal status varies by country and often depends on whether the material is presented as a research chemical, supplement, or drug.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Fragment analog of human growth hormone |
| Sequence basis | hGH 176–191 region | Modified C-terminal fragment |
| Common synonyms | AOD-9604; AOD9604; hGH fragment | Research and trade names vary |
| Regulatory status | Not approved as a drug | Prohibited in competitive sport |
| Research code | AOD9604 | Used in scientific and patent literature |
In the scientific literature, AOD-9604 appears in reviews of growth hormone fragments and in discussions of peptide-based metabolic research. Some sources distinguish it from growth hormone itself, while others group it with compounds marketed for weight management. The evidence base is small compared with approved obesity medications. Questions about long-term efficacy and clinical relevance remain open, and independent replication of key findings is limited. Most published reports are early-stage and exploratory.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It is often described as hGH fragment 176-191. Research interest arose because it was designed to isolate possible effects on fat metabolism from other actions of growth hormone. It is not a full growth hormone molecule. Its development history includes early laboratory and animal studies followed by human trials. The peptide has been examined in laboratory, animal, and limited human studies.
Several names appear in scientific and commercial settings. AOD9604 and AOD-9604 are development codes used interchangeably, while hGH fragment 176-191 describes the same region. The peptide includes a disulfide bond between two cysteine residues, which helps shape its three-dimensional structure. Different suppliers may provide acetate or other salt forms, and purity can vary. These differences matter because analytical tests and biological assays can respond to the specific form being studied.
Early interest in AOD-9604 centered on whether a fragment of human growth hormone could influence fat metabolism without the broader effects of the full hormone. Cell and animal studies reported changes in fat storage and breakdown. Human trials followed, but the results were not strong enough to secure regulatory approval. The compound remains available for laboratory research, and its clinical potential is still described as uncertain. Studies continue to examine its activity and safety profile.
AOD-9604 is a synthetic peptide that corresponds to a short section of human growth hormone. It is commonly identified as hGH fragment 176-191 because its sequence matches residues at the C-terminal end of the hormone. The molecule contains sixteen amino acids and is made by solid-phase peptide synthesis. Researchers study it for metabolic effects rather than for the growth-promoting actions associated with full human growth hormone. Its small size distinguishes it from the complete 191-amino-acid hormone.
AOD-9604 is a synthetic peptide whose sequence matches the C-terminal fragment of human growth hormone, specifically residues 176 through 191. This region differs from the full hormone in its receptor interactions. The peptide is not a growth hormone secretagogue and does not bind the growth hormone receptor in the same manner. Researchers have examined it for effects on lipid metabolism, but its exact pharmacological profile remains an active area of study.
Development of AOD-9604 began in the 1990s as scientists sought to isolate metabolic effects of growth hormone without its growth-promoting actions. Early laboratory work focused on fat cells and animal models. Several human trials followed, examining changes in body composition and fat mass. Results have been mixed, and the peptide has not progressed to widespread clinical approval. Interest continues in research settings, particularly regarding its mechanism and potential metabolic targets.
Cold Case Investigation Units TELEMASP Bulletin, Texas Law Enforcement Management and Administrative Statistics Program Wagner, Adam (2012-01-04). "Why Stephen Lawrence's killers were sentenced as juveniles". The Guardian. Retrieved 2012-01-04. – explains sentencing in the UK, for cases that took place long ago.
=== Promotion in the United States === In 1977, the Associated Press delivered the first news story in the United States about powdered alcohol, which was then an unprecedented product. Investors were quoted as saying that they "hope[d] to revolutionize the liquor business with a product that's easy to carry, cheap and potent". A test sale of powdered alcohol, called "SureShot", was done in the United States.
=== EC 2.7.11: Protein-serine/threonine kinases === EC 2.7.11.1: non-specific serine/threonine protein kinase EC 2.7.11.2: [pyruvate dehydrogenase (acetyl-transferring)] kinase EC 2.7.11.3: dephospho-(reductase kinase) kinase EC 2.7.11.4: (3-methyl-2-oxobutanoate dehydrogenase (acetyl-transferring)) kinase EC 2.7.11.5: [isocitrate dehydrogenase (NADP+)] kinase EC 2.7.11.6: [tyrosine 3-monooxygenase] kinase EC 2.7.11.7: myosin-heavy-chain kinase EC 2.7.11.8: Fas-activated serine/threonine kinase EC 2.7.11.9: Goodpasture-antigen-binding protein kinase EC 2.7.11.10: IkB kinase EC 2.7.11.11: cAMP-dependent protein kinase EC 2.7.11.12: cGMP-dependent protein kinase EC 2.7.11.13: protein kinase C EC 2.7.11.14: rhodopsin kinase EC 2.7.11.15: β-adrenergic-receptor kinase EC 2.7.11.16: G-protein-coupled receptor kinase EC 2.7.11.17: Ca2+/calmodulin-dependent protein kinase EC 2.7.11.18: myosin-light-chain kinase EC 2.7.11.19: phosphorylase kinase EC 2.7.11.20: elongation factor 2 kinase EC 2.7.11.21: polo kinase EC 2.7.11.22: cyclin-dependent kinase EC 2.7.11.23: [RNA-polymerase]-subunit kinase EC 2.7.11.24: mitogen-activated protein kinase EC 2.7.11.25: mitogen-activated protein kinase kinase kinase EC 2.7.11.26: tau-protein kinase EC 2.7.11.27: [acetyl-CoA carboxylase] kinase EC 2.7.11.28: tropomyosin kinase EC 2.7.11.29: low-density-lipoprotein receptor kinase EC 2.7.11.30: receptor protein serine/threonine kinase EC 2.7.11.31: [hydroxymethylglutaryl-CoA reductase (NADPH)] kinase EC 2.7.11.32: [pyruvate, phosphate dikinase] kinase EC 2.7.11.33: [pyruvate, water dikinase] kinase
== LSI Symposium == The LSI Annual Symposium invites leading scientists from different disciplines to converge around a single topic. Past symposia have been designed to explore genetic insights into biology and disease, cancer, stem cell biology, evolutionary biology, autophagy and diseases of the nervous system.
LED airport fixtures currently include medium-intensity runway lights, runway centerline lights, taxiway centerline and edge lights, guidance signs, and obstruction lighting. LEDs are also used as a light source for DLP projectors, and to backlight newer LCD television (referred to as LED TV), computer monitor (including laptop) and handheld device LCDs, succeeding older CCFL-backlit LCDs although being superseded by OLED screens. RGB LEDs raise the color gamut by as much as 45%. Screens for TV and computer displays can be made thinner using LEDs for backlighting. LEDs are small, durable and need little power, so they are used in handheld devices such as flashlights. LED strobe lights or camera flashes operate at a safe, low voltage, instead of the 250+ volts commonly found in xenon flashlamp-based lighting. This is especially useful in cameras on mobile phones, where space is at a premium and bulky voltage-raising circuitry is undesirable. LEDs are used for infrared illumination in night vision uses including security cameras. A ring of LEDs around a video camera, aimed forward into a retroreflective background, allows chroma keying in video productions.
Sources: en.wikipedia.org
Brian Clarke, Artist. For services to Art. Ronald Dennis, , Chair, Podium Analytics and Patron, Tommy's Campaign. For services to Industry and to Charity. Gregory Doran, lately Artistic Director, Royal Shakespeare Company. For services to the Arts. Athelstan Joseph Michael Eavis, , Founder and Leader, Glastonbury Festival. For services to Music and to Charity. Professor William John Edmunds, , Professor, Faculty of Epidemiology and Population Health, London School of Hygiene and Tropical Medicine. For services to Epidemiology. John Patrick Griffin, Founder, Addison Lee. For services to Business and to Charity. Stephen Alan Michael Hester, Chair, Easyjet and Chair, Nordea. For services to Business and to the Economy. David Charles Holmes, , Chief Executive Officer, Family Action. For services to Children and Families. Professor Amritpal Singh Hungin, , Emeritus Professor of General Practice, Newcastle University. For services to Medicine. Professor John Peter Iredale, , lately Interim Executive Chair, Medical Research Council. For services to Medical Research. The Right Honourable Sajid Javid, , Member of Parliament for Bromsgrove. For Political and Public Service. Timothy Randall Martin, Founder and Chair, Wetherspoons. For services to Hospitality and to Culture. Professor Alexander McCall Smith, , Author and Academic. For services to Literature, to Academia and to Charity Professor Neil James McCready Mortensen, lately President, Royal College of Surgeons of England. For services to Surgery. Gerald Maurice Ronson, , For services to Philanthropy and to the Jewish Community.
== Labor shortage == Medical facilities throughout the United States have gradually been experiencing a shortage in medical laboratory science professionals. The current projectory of medical laboratory personnel through 2030 is insufficient to serve medical services effectively. Reasons for the shortage include current professionals retiring, a modern increase in medical laboratory scientist and technician demand, changes in the practice caused by new technological advances (which need training to learn to use), and vacancy and retirement rates being greater than the number of graduates from medical laboratory programs. Lack of funding, low salaries, lack of a developed career ladder, and a lack of clear job requirements has made recruitment and the hiring process difficult. Newer recruiting attempts have increased the number of graduated professionals in the last five years, but not enough to meet the growing demand. Some clinical organizations suggest that professional-development programs for the allied health fields should be improved to cultivate interest in younger professionals and students. The Institute of Medicine is actively working on re-viewing policy reforms and new plans and recommendations to increase medical professional turnout among younger people. The COVID-19 pandemic highlighted the medical laboratory shortage in the medical field. Organizations such as the American Society for Clinical Laboratory Science and the American Society for Clinical Pathology are pushing for new ways to reduce this shortage and meet the demands of the public.
6-MAM already has a free 3-hydroxy group and shares the high lipophilicity of heroin, so it penetrates the brain just as quickly and does not need to be deacetylated at the 6-position in order to be bioactivated; this makes 6-MAM somewhat more potent than heroin.
In relation to its selectivity for the AR, unlike steroidal antiandrogens (SAAs) such as CPA and megestrol acetate (MGA), bicalutamide does not interact importantly with other steroid hormone receptors (including the ERsTooltip estrogen receptors, PRsTooltip progesterone receptors, GRTooltip glucocorticoid receptor, or MRTooltip mineralocorticoid receptor), and in accordance, has no clinically relevant additional, off-target hormonal activity (estrogenic or antiestrogenic, progestogenic or antiprogestogenic, glucocorticoid or antiglucocorticoid, or mineralocorticoid or antimineralocorticoid). However, it has been reported that bicalutamide has weak affinity for the progesterone receptor (PR) (~100- to 500-fold lower than for the AR), where it acts as an antagonist (with only ~12-fold lower functional inhibition relative to the AR in one study). Hence, bicalutamide may have some antiprogestogenic activity, although the clinical relevance of this is unknown. Bicalutamide does not inhibit 5α-reductase and is not known to inhibit other enzymes involved in androgen steroidogenesis (e.g., CYP17A1). Although bicalutamide does not bind to the ERs, it can increase estrogen levels secondarily to blockade of the AR when used as a monotherapy in males, and for this reason, the medication can indirectly activate the ERs to a degree and hence have some indirect estrogenic effects in men.
On April 25, 2023, Musk announced that posts by verified accounts would now be prioritized ahead of unverified users, but behind those of the user's own follows, in replies to tweets. On April 30, 2023, multiple legacy verified users began noticing a bug that temporarily restored the legacy blue checkmark by changing their bio. On October 17, 2023, X announced that it would trial a scheme requiring new users who register via the website in New Zealand and the Philippines to pay US$1 per-year in order to use the platform. If the user does not subscribe, they will only receive read-only access to the platform. It was stated that this system was required to "bolster our already significant efforts to reduce spam, manipulation of our platform and bot activity."
Sources: en.wikipedia.org
No. It is a synthetic peptide fragment modeled on part of human growth hormone, not the full hormone. It does not contain the complete sequence or receptor-binding regions of hGH.
It was investigated in clinical trials for obesity, but it did not receive approval for that use in major markets. Results were generally modest or mixed, and it remains an experimental compound.
WADA lists it as a prohibited peptide hormone. Its use can be detected by laboratory methods, and athletes are subject to sanctions if it is found in samples.
No major regulatory agency has approved AOD-9604 as a medicine. It is treated as an experimental peptide in research settings. Some countries restrict its sale or import.